Edition:
United States

Forward Pharma A/S (FWP.OQ)

FWP.OQ on NASDAQ Stock Exchange Global Select Market

3.44USD
3:59pm EST
Change (% chg)

$-0.14 (-3.91%)
Prev Close
$3.58
Open
$3.60
Day's High
$3.60
Day's Low
$3.38
Volume
68,174
Avg. Vol
17,365
52-wk High
$32.70
52-wk Low
$3.18

Latest Key Developments (Source: Significant Developments)

Forward Pharma Files Further Written Submissions In European Opposition Proceeding For EP2801355 Patent
Wednesday, 29 Nov 2017 04:30pm EST 

Nov 29 (Reuters) - Forward Pharma A/S ::FORWARD PHARMA FILES FURTHER WRITTEN SUBMISSIONS IN THE EUROPEAN OPPOSITION PROCEEDING FOR THE EP2801355 PATENT IN PREPARATION FOR THE ORAL HEARING IN JANUARY 2018.FORWARD PHARMA A/S - FILING OF FURTHER WRITTEN SUBMISSIONS IN EUROPEAN OPPOSITION PROCEEDING FOR EP2801355 PATENT WITH EPO.FORWARD PHARMA A/S - FILING WILL BECOME PUBLICLY AVAILABLE VIA EUROPEAN PATENT REGISTER.FORWARD PHARMA A/S - AN ORAL HEARING IS CURRENTLY SCHEDULED FOR JANUARY 29-30, 2018.FORWARD PHARMA A/S - POSSIBILITY TO APPEAL DECISION OF OPPOSITION DIVISION TO TECHNICAL BOARD OF APPEAL.  Full Article

Forward Pharma announces completion of corporate restructuring plan
Wednesday, 22 Nov 2017 04:30pm EST 

Nov 22 (Reuters) - Forward Pharma A/S :Forward Pharma announces completion of corporate restructuring plan.  Full Article

Forward pharma says filing in U.S. Court to appeal PTAB decision​
Tuesday, 5 Sep 2017 05:00pm EDT 

Sept 5 (Reuters) - Biogen Inc :Forward pharma a/s says filing in a u.s. Court of opening brief for appeal of a ptab decision​.Forward pharma - ‍the ptab decision ended interference proceeding between forward's 11/576,871 patent application and an issued biogen patent​.Forward pharma - ‍after biogen files its responsive brief, currently due oct 16, 2017, forward is allowed a reply brief, currently due october 30, 2017​.Forward pharma a/s - ‍an oral argument is expected to be held before the federal circuit in late 2017 or early 2018​.  Full Article

Forward Pharma board approves capital reduction
Friday, 1 Sep 2017 07:00am EDT 

Sept 1 (Reuters) - Forward Pharma A/S :Forward Pharma board of directors approves capital reduction and returns EUR 917.7 million to shareholders.Forward Pharma A/S - the company effected the capital reduction with a distribution of proceeds to holders of ordinary shares‍​.Forward Pharma A/S - ‍record date for holders of ADS to receive a ratable portion of capital reduction will be September 7, 2017​.Forward Pharma A/S - ‍ADSs are expected to begin trading "ex-dividend" on September 12, 2017​.  Full Article

Forward Pharma obtains shareholder approval of capital reduction
Wednesday, 2 Aug 2017 04:45pm EDT 

Aug 2 (Reuters) - Forward Pharma A/S :Forward Pharma obtains shareholder approval of the planned capital reduction at the extraordinary general meeting.Forward Pharma A/S - got ruling from Danish tax authorities covering holders of ordinary shares and holders of Forward's American depositary shares​.Forward Pharma A/S - ‍based on ruling, company will not be withholding any part of proceeds from capital reduction for Danish tax​.Forward Pharma A/S - ‍majority of votes cast at shareholder meeting approved plans to return EUR 917.7 million to shareholders through a capital reduction​.  Full Article

Forward Pharma announces planned distribution of EUR 19.45 per share to shareholders
Tuesday, 18 Jul 2017 08:05am EDT 

July 18 (Reuters) - Forward Pharma A/S ::Forward Pharma announces planned distribution of EUR 19.45 per share to shareholders.Forward Pharma A/S - plans to return EUR 19.45 per share amounting to a total of EUR 917.7 million to its shareholders through a capital reduction.Forward Pharma A/S - plans to complete capital reduction in early September 2017.Forward Pharma - decision is based on careful evaluation of most appropriate capital allocation strategy after receipt of non-refundable $1.25 billion cash fee from Biogen.Forward Pharma - capital reduction aligns amount of working capital with adjusted business activities following settlement and license agreement with Biogen.Forward Pharma A/S - shareholders representing over two-thirds of voting share capital have irrevocably agreed to vote in favor of capital reduction.  Full Article

Forward Pharma says chief financial officer Joel Sendek has left company
Monday, 1 May 2017 07:30am EDT 

May 1 (Reuters) - Forward Pharma A/S -:Forward Pharma further aligns cost structure with focus following settlement and license agreement.Forward Pharma A/S - chief financial officer Joel Sendek has left company, effective april 30, 2017.Forward Pharma A/S - executive vice presidents rupert sandbrink and andrzej stano will be leaving company in q3 of 2017.FORWARD PHARMA- some non-executive roles primarily in research and development to be made redundant, with goal of reducing total number of full-time employees to below 7.  Full Article

Forward Pharma reports Q4 earnings per share $0.20
Tuesday, 18 Apr 2017 05:15pm EDT 

April 18 (Reuters) - Forward Pharma A/S -:Forward Pharma reports fourth quarter and year end 2016 financial and operational results.Forward Pharma A/S qtrly earnings per share $0.20.Forward Pharma A/S qtrly non-gaap loss per share $0.25.Forward Pharma A/S - intend to release future financial results semi-annually, with next report following the end of second quarter.  Full Article

Forward Pharma appoints Claus Bo Svendsen as CEO
Wednesday, 1 Mar 2017 09:15am EST 

Forward Pharma A/S : Forward Pharma appoints Claus Bo Svendsen as chief executive officer and plans to reorganize to reduce burn rate following the settlement and license agreement with biogen . Forward Pharma A/S - Svendsen succeeds Peder M. Andersen . Forward Pharma A/S - plans to wind up its remaining research and development efforts . Forward Pharma A/S - Andersen will retain his role as chief operating officer and serve until September 1, 2017 .Forward Pharma A/S - plans to pursue an organizational realignment to reduce personnel and operating expenses by mid-year 2017.  Full Article

Forward Pharma enters license agreement with 2 units of Biogen and other parties
Wednesday, 1 Feb 2017 09:15am EST 

Forward Pharma A/S : Approved entry into settlement, license agreement with 2 wholly owned subsidiaries of Biogen Inc and certain other parties .Forward Pharma - entitled to a non-refundable cash fee of us$1.25 billion within five business days of meeting pursuant to terms of license agreement.  Full Article

BRIEF-Forward Pharma Files Further Written Submissions In European Opposition Proceeding For EP2801355 Patent

* FORWARD PHARMA FILES FURTHER WRITTEN SUBMISSIONS IN THE EUROPEAN OPPOSITION PROCEEDING FOR THE EP2801355 PATENT IN PREPARATION FOR THE ORAL HEARING IN JANUARY 2018